BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $74,240 | +93.5% | 1,967,197 | +133.6% | 0.05% | +91.7% |
Q2 2023 | $38,366 | +0.4% | 842,096 | -10.6% | 0.02% | +33.3% |
Q1 2023 | $38,209 | -41.1% | 941,988 | -25.9% | 0.02% | -37.9% |
Q4 2022 | $64,822 | -99.9% | 1,271,787 | +19.9% | 0.03% | -53.2% |
Q3 2022 | $57,138,000 | +0.8% | 1,060,823 | +20.2% | 0.06% | +77.1% |
Q2 2022 | $56,706,000 | -31.1% | 882,849 | -16.8% | 0.04% | -45.3% |
Q1 2022 | $82,317,000 | -51.8% | 1,061,620 | -46.7% | 0.06% | +100.0% |
Q4 2021 | $170,924,000 | +175.7% | 1,991,218 | +158.3% | 0.03% | +14.3% |
Q3 2021 | $61,991,000 | +1.8% | 770,758 | +1.9% | 0.03% | -3.4% |
Q2 2021 | $60,893,000 | +49.4% | 756,430 | +56.6% | 0.03% | +31.8% |
Q1 2021 | $40,749,000 | +18.5% | 483,165 | +12.7% | 0.02% | +22.2% |
Q4 2020 | $34,386,000 | -78.6% | 428,540 | -78.6% | 0.02% | -81.2% |
Q3 2020 | $160,986,000 | +485.0% | 2,001,852 | +526.4% | 0.10% | +357.1% |
Q2 2020 | $27,519,000 | +43.8% | 319,591 | +35.6% | 0.02% | +50.0% |
Q1 2020 | $19,140,000 | -72.0% | 235,706 | -71.2% | 0.01% | -64.1% |
Q4 2019 | $68,431,000 | -8.1% | 818,353 | -3.8% | 0.04% | -15.2% |
Q3 2019 | $74,449,000 | +11.4% | 851,117 | +4.3% | 0.05% | +12.2% |
Q2 2019 | $66,855,000 | -10.1% | 816,305 | -10.7% | 0.04% | -19.6% |
Q1 2019 | $74,365,000 | -18.1% | 914,570 | -33.7% | 0.05% | -27.1% |
Q4 2018 | $90,848,000 | +39.4% | 1,380,254 | +63.3% | 0.07% | +55.6% |
Q3 2018 | $65,168,000 | +30.6% | 845,364 | +25.1% | 0.04% | +4.7% |
Q2 2018 | $49,903,000 | -28.1% | 675,835 | -36.7% | 0.04% | -18.9% |
Q1 2018 | $69,450,000 | -6.8% | 1,067,812 | -7.3% | 0.05% | -11.7% |
Q4 2017 | $74,492,000 | +157.0% | 1,152,403 | +149.5% | 0.06% | +100.0% |
Q3 2017 | $28,989,000 | +39.0% | 461,960 | +34.1% | 0.03% | +36.4% |
Q2 2017 | $20,851,000 | +25.7% | 344,389 | +7.6% | 0.02% | +29.4% |
Q1 2017 | $16,591,000 | -21.5% | 319,942 | -32.9% | 0.02% | -26.1% |
Q4 2016 | $21,140,000 | -31.4% | 476,753 | -26.4% | 0.02% | -34.3% |
Q3 2016 | $30,818,000 | -14.5% | 647,407 | -18.8% | 0.04% | -23.9% |
Q2 2016 | $36,047,000 | +38.0% | 797,158 | +25.1% | 0.05% | +15.0% |
Q1 2016 | $26,121,000 | -23.9% | 637,089 | -29.4% | 0.04% | -4.8% |
Q4 2015 | $34,305,000 | +5.8% | 902,782 | -10.9% | 0.04% | +7.7% |
Q3 2015 | $32,411,000 | -71.7% | 1,013,042 | -39.0% | 0.04% | -69.5% |
Q2 2015 | $114,636,000 | +38.1% | 1,661,311 | +36.1% | 0.13% | +33.3% |
Q1 2015 | $82,996,000 | -49.8% | 1,220,410 | -46.1% | 0.10% | -39.6% |
Q4 2014 | $165,415,000 | +35.7% | 2,265,814 | +32.0% | 0.16% | +35.9% |
Q3 2014 | $121,915,000 | +135.9% | 1,717,015 | +139.2% | 0.12% | +112.7% |
Q2 2014 | $51,672,000 | -43.5% | 717,793 | -42.7% | 0.06% | -47.1% |
Q1 2014 | $91,387,000 | -28.5% | 1,251,794 | -32.4% | 0.10% | -20.6% |
Q4 2013 | $127,859,000 | +13.7% | 1,853,033 | +7.1% | 0.13% | -2.2% |
Q3 2013 | $112,488,000 | -40.2% | 1,730,567 | -36.3% | 0.13% | -42.7% |
Q2 2013 | $188,160,000 | – | 2,716,322 | – | 0.23% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |